Keeping Track: FDA Issues Three Four-Month Approvals: Ninlaro, Darzalex, And Narcan Nasal Spray

The latest drug development news and highlights from our FDA Performance Tracker.

This week, FDA approved two novel multiple myeloma therapies after fast, four-month reviews: Takeda Pharmaceutical Co. Ltd. 's Ninlaro (ixazomib) and Johnson & Johnson /Genmab AS's breakthrough-designated Darzalex (daratumumab).

A four-month reivew is an internal goal often set by the Office of Hematology and Oncology Products for products that...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D